Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Trading Arrangement: Trading Arrangement [Axis] Reclassification adjustments related to amortization of prior service costs and other, net Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Sciwind Biosciences Sciwind Biosciences [Member] Sciwind Biosciences Title of 12(b) Security Title of 12(b) Security Net income/(loss) attributable to Pfizer Inc. common shareholders Net Income (Loss) Available to Common Stockholders, Diluted Carrying Value [Member] Reported Value Measurement [Member] Subsequent Event [Member] Subsequent Event [Member] Net Sales and Royalty Agreement Terms [Member] Net Sales And Royalty Agreement Terms [Member] Net Sales And Royalty Agreement Terms Adjustment to Compensation, Amount Adjustment to Compensation Amount FDA Approval of MET-097i [Member] FDA Approval of MET-097i [Member] FDA Approval of MET-097i Financial Instrument [Axis] Financial Instrument [Axis] Segment Reporting [Abstract] Segment Reporting [Abstract] Restructuring Plan [Axis] Restructuring Plan [Axis] Revenue from External Customers by Products and Services [Table] Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Table] Accrued compensation and related items Employee-related Liabilities, Current Pension and Postretirement Benefit Plans Retirement Benefits [Text Block] Haleon [Member] Haleon [Member] Haleon Integration costs and other Business Combination, Integration-Related Cost, Expense Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract] Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract] Derivative Instrument [Axis] Derivative Instrument [Axis] Schedule Of Accrued Liabilities [Line Items] Schedule Of Accrued Liabilities [Line Items] [Line Items] for Schedule Of Accrued Liabilities [Table] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Developed technology rights [Member] Developed Technology Rights [Member] Enbrel (Outside the U.S. and Canada) [Member] Enbrel [Member] Enbrel [Member] Noncurrent inventories not included above Inventory, Noncurrent Schedule of Gains and Losses on Investment Securities Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block] Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block] Debt Securities, Held-to-maturity, Maturity [Abstract] Debt Securities, Held-to-Maturity, Maturity [Abstract] Schedule Of Accrued Liabilities [Table] Schedule Of Accrued Liabilities [Table] Schedule Of Accrued Liabilities [Table] Schedule of Held-to-maturity Securities Debt Securities, Held-to-Maturity [Table Text Block] Tivdak [Member] Tivdak [Member] Tivdak Realigning Our Cost Base Program - Initial Phase [Member] Realigning Our Cost Base Program - Initial Phase [Member] Realigning Our Cost Base Program - Initial Phase Available-for-sale Securities, Debt Maturities [Abstract] Available-for-Sale Securities, Debt Maturities [Abstract] Identifiable intangible assets, net Identifiable Intangible Assets, less Accumulated Amortization Intangible Asset, Excluding Goodwill, after Accumulated Amortization Retirement Benefits [Abstract] Retirement Benefits [Abstract] Foreign currency short-term borrowings [Member] Foreign Currency Short Term Borrowings [Member] Foreign currency short - term borrowings [Member] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Schedule of Components of Inventories, Noncurrent Schedule of Inventory, Noncurrent [Table Text Block] Number of reportable segments Number of Reportable Segments Total current liabilities Liabilities, Current Total Alliance revenues [Member] Total Alliance Biopharmaceuticals [Member] Total Alliance Biopharmaceuticals [Member] Subsegments Consolidation Items [Axis] Subsegments Consolidation Items [Axis] Work-in-process Inventory, Work in Process, Net of Reserves Current derivative liabilities Derivative Liability, Current Schedule of Derivative Instruments Schedule of Derivative Instruments [Table Text Block] Schedule of Derivative Assets Schedule of Derivative Assets at Fair Value [Table Text Block] Entity Address, City or Town Entity Address, City or Town Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] International [Member] Foreign Plan [Member] Benefit plan contributions in excess of expense/income Pension And Other Postretirement Benefit Contributions, Net Of Pension And Other Postretirement Benefit (Expense) The amount of cash or cash equivalents contributed during the reporting period by the entity to fund its pension plans and its non-pension postretirement benefit plans less the amount of pension and other postretirement benefit costs/income recognized during the period for defined benefit plans (periodic benefit costs/income include the following components: service cost, interest cost, expected return on plan assets, gain or loss on assets, prior service cost or credit, transition asset or obligation, and gain or loss due to settlements or curtailments). Product [Member] Product [Member] Finite-lived intangible assets, net Intangible Asset, Finite-Lived, after Accumulated Amortization Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Other comprehensive income/(loss) before allocation to noncontrolling interests Other comprehensive income/(loss), net of tax Other Comprehensive Income (Loss), Net of Tax Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Total other current liabilities Liabilities, Current, Fair Value Disclosure Liabilities, Current, Fair Value Disclosure U.S. [Member] UNITED STATES Government and Government Sponsored [Member] Government and Government Sponsored [Member] Government and Government Sponsored Subsequent Event Type [Axis] Subsequent Event Type [Axis] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Schedule of Segment Reporting Information by Segment Segment Reporting [Table Text Block] Cumulative upward price adjustments on equity securities Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount Trade Accounts Receivable Revenue from Contract with Customer [Policy Text Block] Schedule of Changes in Contingent Consideration Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Current tax assets Other Tax Assets, Current Other Tax Assets, Current Private equity securities at cost Private Equity Investments Private Equity Investments Available-for-sale securities, debt maturities, over 1 to 5 years, fair value Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Document Period End Date Document Period End Date Notes Due 2029, 2.875% [Member] Notes Due 2029, 2.875% [Member] Notes Due 2029, 2.875% Earnings/(loss) per common share––basic: EPS/(LPS) Numerator Earnings Per Share, Basic [Abstract] Restructuring cost incurred to date Restructuring and Related Cost, Cost Incurred to Date Treasury stock Treasury Stock, Common, Value Specialty Care [Member] Specialty Care [Member] Specialty Care Unrealized holding gains/(losses) on available-for-sale securities, net OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Shell Company Entity Shell Company Consolidation Items [Domain] Consolidation Items [Domain] Total other noncurrent assets Other Assets, Noncurrent, Fair Value Disclosure Other Assets, Noncurrent, Fair Value Disclosure Earnings/(Loss) Per Common Share Attributable to Pfizer Inc. Common Shareholders Earnings Per Share [Text Block] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items] Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Total liabilities Liabilities Trading Symbol Trading Symbol Reclassification adjustments related to curtailments of prior service costs and other, net Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), before Tax Pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans prior service (costs)/credits. Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Name Company Selected Measure Name Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] GlaxoSmithKline Biologics SA and GlaxoSmithKline LLC US Patent Infringement Case [Member] GlaxoSmithKline Biologics SA And GlaxoSmithKline LLC US Patent Infringement Case [Member] GlaxoSmithKline Biologics SA And GlaxoSmithKline LLC US Patent Infringement Case Schedule of Indefinite-Lived Intangible Assets [Table] Intangible Asset, Indefinite-Lived [Table] Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Earnings/(loss) per common share––diluted: Earnings Per Share, Diluted [Abstract] Operating Activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Cash expenditures, percentage of expected cost Restructuring and Related Cost, Cash Expenditures, Percentage of Expected Cost Restructuring and Related Cost, Cash Expenditures, Percentage of Expected Cost Dividends payable Dividends Payable, Current Indefinite-lived Intangible Assets [Line Items] Intangible Asset, Indefinite-Lived [Line Items] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Entities [Table] Entities [Table] Research and development arrangement, maximum funding amount Research And Development Arrangement, Maximum Funding Amount Research And Development Arrangement, Maximum Funding Amount Common-share equivalents (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Award Timing Predetermined Award Timing Predetermined [Flag] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Reclassification adjustments related to curtailments of prior service costs and other, net Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax Noncurrent derivative assets Derivative Asset, Noncurrent Held-to-maturity debt securities Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current Effective tax rate for income from continuing operations Effective Income Tax Rate Reconciliation, Percent In-Licensing Agreement [Member] In-Licensing Agreement [Member] In-Licensing Agreement Income/(loss) from continuing operations Net income from continuing operations before allocation to noncontrolling interests Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Derivative, Amount of Gains/(Losses), Hedged Item, Recognized in OID Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Ibrance [Member] Ibrance [Member] Ibrance [Member] Long-term debt, fair value Long-Term Debt, Fair Value Amortization of intangible assets Amortization Of Intangible Assets Not Associated With Single Function The amount of amortization that is not associated with a single function. Amounts associated in a single function are included in Cost of sales, Selling, information and administrative expenses and Research and development expenses. Fair Value Disclosures [Abstract] Royalty [Member] Royalty [Member] Derivative, Amount of Gains/(Losses), Fair Value Hedge, Recognized in OID Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Reclassification, Type [Domain] Reclassification, Type [Domain] Expiration Date Trading Arrangement Expiration Date Hedging Relationship [Axis] Hedging Relationship [Axis] Held-to-maturity securities, gross unrealized gains Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain International Developed Markets [Member] International Developed Markets [Member] International Developed Markets Total equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Debt securities maturities, over 1 to 5 years, fair value Debt Securities Maturities, Year Two Through Five, Fair Value Debt Securities Maturities, Year Two Through Five, Fair Value Cash dividends declared: Dividends [Abstract] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Derivative [Table] Derivative [Table] Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Orgovyx [Member] Orgovyx [Member] Orgovyx Investing Activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Litigation Status [Axis] Litigation Status [Axis] Segments [Domain] Segments [Domain] Utilization and other Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives Restructuring and Related Costs [Table Text Block] Business Combination [Table] Business Combination [Table] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Common stock Dividends, Common Stock, Cash Total Pfizer Inc. shareholders’ equity Equity, Attributable to Parent Assets Assets [Abstract] Available-for-sale debt securities, amortized cost Debt Securities, Available-for-Sale, Amortized Cost Insider Trading Policies and Procedures [Line Items] Threshold for disclosure of proceedings under environmental laws Site Contingency, Regulatory Proceedings, Disclosure Threshold Site Contingency, Regulatory Proceedings, Disclosure Threshold Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Deferred taxes Deferred Income Tax Expense (Benefit) Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items] Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items] Available-for-sale securities, debt maturities, over 5 years, fair value Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value Anti-dilutive common stock equivalents (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Number of operating segments Number of Operating Segments Entity Central Index Key Entity Central Index Key Property, plant and equipment, accumulated depreciation Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization Equity [Abstract] Equity [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Other Stockholders' Equity, Other Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Investment, Name [Axis] Investment, Name [Axis] Derivatives designated as hedging instruments [Member] Designated as Hedging Instrument [Member] Designated as Hedging Instrument [Member] Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax Additional depreciation––asset restructuring recorded in Cost of sales Restructuring and Related Cost, Accelerated Depreciation FDA Approval of MET-097i + MET-233i [Member] FDA Approval of MET-097i + MET-233i [Member] FDA Approval of MET-097i + MET-233i Accum. Other Comp. Loss [Member] Accumulated Other Comprehensive Income (Loss) [Member] AOCI Attributable to Parent [Member] All Individuals All Individuals [Member] Schedule of Revenues by Geographic Region Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue [Table Text Block] Finished goods Inventory, Finished Goods, Net of Reserves Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Contingent consideration liabilities Business Combination, Contingent Consideration, Liability, Noncurrent Developed technology rights Finite-Lived Intangible Assets, Fair Value Disclosure Statement [Line Items] Statement [Line Items] Total assets Total assets Assets GlaxoSmithKline Biologics SA And GlaxoSmithKline LLC Unified Patent Court Patent Infringement Case [Member] GlaxoSmithKline Biologics SA And GlaxoSmithKline LLC Unified Patent Court Patent Infringement Case [Member] GlaxoSmithKline Biologics SA And GlaxoSmithKline LLC Unified Patent Court Patent Infringement Case Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan [Table] Current portion of long-term debt, principal amount Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting Less: Net (gains)/losses recognized during the period on equity securities sold during the period Equity Securities, FV-NI, Realized Gain (Loss) Operating Segments [Member] Operating Segments [Member] Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Liability Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease) Reclassification adjustments for (gains)/losses included in net income/(loss) Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax Available-for-sale debt securities, gross unrealized gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Octagam [Member] Octagam [Member] Octagam PEO PEO [Member] Other noncurrent liabilities Other Liabilities, Noncurrent International Commercial Division [Member] International Commercial Division [Member] International Commercial Division Goodwill Goodwill Goodwill Retirement Plan Type [Axis] Retirement Plan Type [Axis] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Vyndaqel family [Member] Vyndaqel [Member] Vyndaqel [Member] Net (gains)/losses recognized during the period on equity securities Net (gains)/losses recognized during the period on equity securities Equity Securities, FV-NI, Gain (Loss) Retained Earnings [Member] Retained Earnings [Member] Global Hospital and Biosimilars Division [Member] Global Hospital and Biosimilars Division [Member] Global Hospital and Biosimilars Division Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Award Timing Disclosures [Line Items] Paxlovid [Member] Paxlovid [Member] Paxlovid Foreign Currency Translation Adjustment [Member] Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Corporate and other [Member] Corporate Debt Securities [Member] Net income/(loss) attributable to Pfizer Inc. common shareholders (in dollars per share) Earnings Per Share, Diluted Notes Due 2037, 3.875% [Member] Notes Due 2037, 3.875% [Member] Notes Due 2037, 3.875% Litigation Case [Domain] Litigation Case [Domain] Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Total costs associated with acquisitions and cost-reduction/productivity initiatives Restructuring Charges, Acquisition Related Costs and Implementation Costs Restructuring Charges, Acquisition Related Costs and Implementation Costs Intangible Asset, Finite-Lived [Line Items] Intangible Asset, Finite-Lived [Line Items] U.S. Commercial Division [Member] U.S. Commercial Division [Member] U.S. Commercial Division Revenues Royalty revenue Revenue from Contract with Customer, Excluding Assessed Tax Arbutus and Genevant U.S. Patent Infringement Case [Member] Arbutus and Genevant U.S. Patent Infringement Case [Member] Arbutus and Genevant U.S. Patent Infringement Case Non-Derivative, Amount of Gains/(Losses) Recognized in OCI Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax Schedule of Derivative Liabilities Schedule of Derivative Liabilities at Fair Value [Table Text Block] Schedule of Components and Changes in Restructuring Accruals Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Non-Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] ModernaTX European Patent Infringement Case [Member] ModernaTX European Patent Infringement Case [Member] ModernaTX European Patent Infringement Case Purchases of short-term investments Payments to Acquire Short-Term Investments Intangible assets, gross carrying amount Intangible Asset, Excluding Goodwill, before Accumulated Amortization Amount of Gains/(Losses) Recognized in OCI Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Before Reclassification and Tax Abingworth [Member] Abingworth [Member] Abingworth Subsegments [Domain] Subsegments [Domain] Loss contingency, patents under review Loss Contingency, Patents Under Review Loss Contingency, Patents Under Review Schedule of Additional Information About Intangible Assets Impaired Intangible Asset, Impairment [Table Text Block] Raw materials and supplies Inventory, Raw Materials and Supplies, Net of Reserves Schedule of Equity Method Investments [Table] Equity Method Investment [Table] Share-based payment transactions Stock Issued During Period, Value, Share Based Compensation and Treasury Stock Value Acquired, Cost Method Stock Issued During Period, Value, Share Based Compensation and Treasury Stock Value Acquired, Cost Method Amount of Gains/(Losses) Recognized in OID Derivative, Gain (Loss) on Derivative, Net All other Specialty Care [Member] Other Specialty Care [Member] Other Specialty Care Remaining performance obligation Revenue, Remaining Performance Obligation, Amount Dividend income Investment Income, Dividend Proceeds from redemptions/sales of long-term investments Proceeds from Sale, Maturity and Collection of Long-Term Investments Government and agency—non-U.S. [Member] Debt Security, Government, Non-US [Member] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Service cost Defined Benefit Plan, Service Cost Derivatives in a net receivable position Derivative, Net Receivable Position, Aggregate Fair Value Derivative, Net Receivable Position, Aggregate Fair Value Gain Contingencies [Line Items] Gain Contingencies [Line Items] Certain asset impairments Asset, Impairment Loss Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Issued GlaxoSmithKline Biologics SA And GlaxoSmithKline LLC Ireland Patent Infringement Case [Member] GlaxoSmithKline Biologics SA And GlaxoSmithKline LLC Ireland Patent Infringement Case [Member] GlaxoSmithKline Biologics SA And GlaxoSmithKline LLC Ireland Patent Infringement Case Entity Information [Line Items] Entity Information [Line Items] Reclassification adjustments related to amortization of prior service costs and other, net Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, Tax Other Financial Information [Abstract] Other Financial Information Available-for-sale debt securities Debt Securities, Available-for-Sale, Current Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests Comprehensive Income (Loss) Note [Text Block] Upfront, regulatory and sales milestone payments Research And Development Arrangement, Upfront, Regulatory and Sales Milestone Payments Research And Development Arrangement, Upfront, Regulatory and Sales Milestone Payments Product and Service [Domain] Product and Service [Domain] Comirnaty [Member] Comirnaty [Member] Comirnaty [Member] Comirnaty Noncurrent deferred tax liabilities Deferred Income Tax Liabilities, Net Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Derivative, Amount of Gains/(Losses) Recognized in OID Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Termination Date Trading Arrangement Termination Date Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Manufacturing Optimization Program - Phase Two [Member] Manufacturing Optimization Program - Phase Two [Member] Manufacturing Optimization Program - Phase Two Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Other current liabilities Other Liabilities, Current Held-to-maturity securities, debt maturities, over 5 years, fair value Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value Current derivative assets Derivative Asset, Current Foreign currency translation adjustments, net Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Fair Value as of Grant Date Award Grant Date Fair Value Loss contingency, number of patents allegedly infringed upon Loss Contingency, Patents Allegedly Infringed, Number Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Number of complaints Number of Complaints Number of Complaints 1.000% Notes due 2027 [Member] Notes Due 2027, 1.000% [Member] Notes Due 2027, 1.000% [Member] Arrangement Duration Trading Arrangement Duration Consolidation Items [Axis] Consolidation Items [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Bosulif [Member] Bosulif [Member] Bosulif [Member] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Finite-lived intangible assets, gross carrying amount Intangible Asset, Finite-Lived, before Accumulated Amortization Total revenues Revenues: Revenues Restructuring charges Restructuring Charges (Credits), Implementation Costs and Additional Depreciation, Asset Restructuring Restructuring Charges (Credits), Implementation Costs and Additional Depreciation, Asset Restructuring Net gain from the sale of investment in ViiV Net gain from the sale of investment in ViiV Equity Method Investment, Realized Gain (Loss) on Disposal Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule Of Available For Sale Securities And Held To Maturity Securities [Line Items] Schedule Of Available For Sale Securities And Held To Maturity Securities [Line Items] Schedule of Available for sale Securities and Held to maturity Securities [Line Items] Intangible Asset, Finite-Lived, Class [Domain] Intangible Asset, Finite-Lived, Class [Domain] Brands [Member] Trade Names [Member] Schedule of Financial Assets and Liabilities Measured At Fair Value On a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] All Award Types Award Type [Domain] Clinical Trial Agreement Terms [Member] Clinical Trial Agreement Terms [Member] Clinical Trial Agreement Terms Derivatives in a net payable position Derivative, Net Liability Position, Aggregate Fair Value Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Government and agency—U.S. [Member] US Government Agencies Debt Securities [Member] Alliance revenues Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer Geographical [Axis] Geographical [Axis] Net periodic benefit costs/(credits) other than service costs Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component Deferred revenues Contract with Customer, Liability Net interest expense Interest Income (Expense), Operating and Nonoperating Foreign currency translation adjustments, net Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax Exit costs Business Exit Costs Carrying Amount of Hedged Assets/Liabilities Hedged Liability, Fair Value Hedge Xeljanz [Member] Xeljanz [Member] Xeljanz [Member] Available-for-sale debt securities Debt Securities, Available-for-Sale, Noncurrent Debt securities, amortized cost Debt Securities, Amortized Cost Basis Debt Securities, Amortized Cost Basis Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period Cash and cash equivalents and restricted cash and cash equivalents, at end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Net fair value adjustments related to hedging and purchase accounting Debt Instrument, Fair Value Adjustments, Hedging And Purchase Accounting, Noncurrent Debt Instrument, Fair Value Adjustments, Hedging And Purchase Accounting, Noncurrent Schedule of Finite-Lived Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Identifiable intangible asset, net Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Indefinite-Lived Braftovi/Mektovi [Member] Braftovi/Mektovi [Member] Braftovi/Mektovi Non-NEOs Non-NEOs [Member] Asset write-offs and impairments Asset Write-Offs And Asset Impairment Charges Asset Write-Offs And Asset Impairment Charges Reporting Unit [Domain] Reporting Unit [Domain] Equity method investment, ownership percentage Equity Method Investment, Ownership Percentage Payments to acquire business, gross Payments to Acquire Businesses, Gross Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract] Debt Securities, Held-to-Maturity, Fair Value, Maturity [Abstract] Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less Payments For (Proceeds From) Short Term Investments With Original Maturities Of Three Months Or Less Payments For (Proceeds From) Short Term Investments With Original Maturities Of Three Months Or Less Customer [Domain] Customer [Domain] Schedule of Components of Inventories, Current Schedule of Inventory, Current [Table Text Block] Investment, Name [Domain] Investment, Name [Domain] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Cresemba [Member] Cresemba [Member] Cresemba Deferred revenues, current Contract with Customer, Liability, Current Information about Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk Derivative Instruments, Gain (Loss) [Table Text Block] Award Type Award Type [Axis] Unrealized holding gains/(losses) on derivative financial instruments, net Derivative, Amount of Gains/(Losses), Cash Flow Hedge, Recognized in OCI Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Interest rate contracts [Member] Interest Rate Contract [Member] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Retained earnings Retained Earnings (Accumulated Deficit) Derivative, Amount of Gains/(Losses) Recognized in OCI, excluded from effectiveness testing and amortized into earnings Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Product and Service [Axis] Product and Service [Axis] Changes in fair value of contingent consideration liabilities Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease) Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Pension Plan [Member] Pension Plan [Member] Common Stock, $.05 par value [Member] Common Stock [Member] Common Stock [Member] Available-for-sale debt securities Available-for-sale debt securities, fair value Debt Securities, Available-for-Sale Supplier finance program payable Supplier Finance Program, Obligation, Current Changes in estimated fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Change in Estimated Fair Value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Change in Estimated Fair Value Employee Termination Costs [Member] Employee Severance [Member] Debt securities maturities, within 1 year, fair value Debt Securities Maturities, Next Twelve Months, Fair Value Debt Securities Maturities, Next Twelve Months, Fair Value Oncology Biosimilars [Member] Oncology Biosimilars [Member] Oncology Biosimilars Derivative Contract [Domain] Derivative Contract [Domain] Total short-term investments Short-term Investments Excluding Held-To-Maturity Securities Short-term Investments Excluding Held-To-Maturity Securities Total liabilities and equity Liabilities and Equity Employee Stock Option Share-Based Payment Arrangement, Option [Member] Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Table] Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Table] Equity attributable to noncontrolling interests Equity, Attributable to Noncontrolling Interest Segments [Axis] Segments [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Schedule of Total Amount of Each Income and Expense Line in which Results of Fair Value Hedges are Recorded Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block] Restructuring charges Restructuring charges/(credits) Provision Restructuring Charges Acquisition-Related Items [Member] Reconciling Items, Acquisition Related Costs [Member] Reconciling Items, Acquisition Related Costs Tabular List, Table Tabular List [Table Text Block] Realigning Our Cost Base Program - Productivity Enhancements Realigning Our Cost Base Program - Productivity Enhancements [Member] Realigning Our Cost Base Program - Productivity Enhancements Additional paid-in capital Additional Paid in Capital Cibinqo [Member] Cibinqo [Member] Cibinqo Accrued rebates Accrued Rebates Accrued Rebates Name Awards Close in Time to MNPI Disclosures, Individual Name Amortization of Intangible Assets [Member] Reconciling Items, Amortization of Intangible Assets [Member] Reconciling Items, Amortization of Intangible Assets Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] All Other Hospital and Biosimilars [Member] All Other Hospital and Biosimilars [Member] All Other Hospital and Biosimilars Foreign currency long-term debt [Member] Foreign Currency Debt [Member] Foreign currency long - term debt [Member] Adjustment to Compensation: Adjustment to Compensation [Axis] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activity Hedging Designation [Axis] Hedging Designation [Axis] Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives Restructuring and Related Activities Disclosure [Text Block] All other Oncology [Member] Other Oncology Products [Member] Other Oncology Products [Member] Total assets Assets, Fair Value Disclosure Name Measure Name Pay vs Performance Disclosure [Line Items] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Debt Instrument [Line Items] Debt Instrument [Line Items] Add'l Paid-in Capital [Member] Additional Paid-in Capital [Member] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Intangible Asset, Indefinite-Lived, Class [Axis] Realigning Our Cost Base Program [Member] Realigning Our Cost Base Program [Member] Realigning Our Cost Base Program Payments on short-term borrowings Repayments of Short-Term Debt Pfizer CentreOne [Member] Pfizer CentreOne [Member] Pfizer CentreOne Implementation costs Implementation Costs Implementation costs represent external, incremental costs directly related to Implementing cost-reduction initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services. Name Trading Arrangement, Individual Name Cash and cash equivalents Cash and Cash Equivalent Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Company Selected Measure Amount Company Selected Measure Amount Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date Equity Securities, FV-NI, Unrealized Gain (Loss) Depreciation and amortization Depreciation and Amortization Depreciation, Depletion and Amortization Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic Phase 3 Clinical Trial [Member] Phase 3 Clinical Trial [Member] Phase 3 Clinical Trial Share-based payment transactions (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Genotropin [Member] Genotropin [Member] Genotropin [Member] Non-PEO NEO Non-PEO NEO [Member] Transfer into/(out of) Level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net Other (Income)/Deductions—Net Other Income and Other Expense Disclosure [Text Block] Cost of sales Cost of Product and Service Sold Award Timing Method Award Timing Method [Text Block] Remaining period of hedging exposure Derivative, Remaining Maturity Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Actuarial (gains)/losses Defined Benefit Plan, Amortization of Gain (Loss) Net income/(loss) attributable to Pfizer Inc. common shareholders Net Income (Loss) Attributable to Parent Number of patents being challenged Gain Contingency, Number of Patents Being Challenged Gain Contingency, Number of Patents Being Challenged Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Balance Sheet Location [Axis] Location, Statement of Financial Position, Balance [Axis] Discontinued operations––net of tax Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Restatement Determination Date: Restatement Determination Date [Axis] Schedule of Changes in Accumulated Other Comprehensive Loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Greenstone Antitrust Litigation [Member] Greenstone Antitrust Litigation [Member] Greenstone Antitrust Litigation Derivative, Amount of Gains/(Losses), Net Investment Hedge, Recognized in OCI Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Research and development arrangement, funding to offset costs incurred Research and Development Arrangement, Funding to Offset Costs Incurred Research and Development Arrangement, Funding to Offset Costs Incurred Collateral posted Collateral Already Posted, Aggregate Fair Value Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] EPS/(LPS) Denominator Weighted Average Number of Shares Outstanding, Diluted [Abstract] Available-for-sale securities, tax, total OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax Document Fiscal Year Focus Document Fiscal Year Focus Customer [Axis] Customer [Axis] Milestone Payments [Domain] Milestone Payments [Domain] Milestone Payments [Domain] Common stock Common Stock, Value, Issued Interest expense Interest Expense, Operating and Nonoperating Schedule of Senior Unsecured Notes Issued, Principal Amounts of Senior Unsecured Long-Term Debt and Adjustments Schedule of Long-Term Debt Instruments [Table Text Block] Sanofi US Patent Infringement Case Sanofi US Patent Infringement Case [Member] Sanofi US Patent Infringement Case Other, net Other Nonoperating Income (Expense), Net Other Nonoperating Income (Expense), Net Restatement Determination Date Restatement Determination Date Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Inventory write-offs––recorded in Cost of sales Inventory Write-down Long-term investments Long-Term Investments [Abstract] Amendment Flag Amendment Flag Proceeds from sale of investment Proceeds from Sale of Equity Method Investments Certain Significant Items [Member] Reconciling Items, Other [Member] Reconciling Items, Other Available-for-sale debt securities, gross unrealized losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Loss Contingencies [Table] Loss Contingencies [Table] Stock awards related to pre-acquisition services Stock Issued During Period, Value, Acquisitions Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Entity Address, State or Province Entity Address, State or Province PEO Total Compensation Amount PEO Total Compensation Amount Notional Derivative, Notional Amount Weighted-average shares--basic (in shares) Weighted-average number of common shares outstanding––Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Maximum potential cash payments Research And Development Arrangement, Contingent Payments, Maximum Exposure1 Research And Development Arrangement, Contingent Payments, Maximum Exposure1 Loss Contingencies [Line Items] Loss Contingencies [Line Items] Manufacturing Optimization Program - Phase One [Member] Manufacturing Optimization Program - Phase One [Member] Manufacturing Optimization Program - Phase One Total short-term borrowings, principal amount Short-term Debt, Gross Short-term Debt, Gross Restructuring charges and certain acquisition-related costs Restructuring Charges (Credits), Inventory Write-Offs, Implementation Costs and Additional Depreciation, Asset Restructuring Restructuring Charges (Credits), Inventory Write-Offs, Implementation Costs and Additional Depreciation, Asset Restructuring Pending Litigation [Member] Pending Litigation [Member] Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Number of cases settled Loss Contingency, Number of Cases Settled Loss Contingency, Number of Cases Settled Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Class of Stock [Axis] Class of Stock [Axis] Net income/(loss) attributable to Pfizer Inc. common shareholders Net Income (Loss) Available to Common Stockholders, Basic Cash dividends paid Payments of Ordinary Dividends Supplemental Cash Flow Information Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract] Finite-lived intangible assets, accumulated amortization Finite-lived intangible assets, accumulated amortization Intangible Asset, Finite-Lived, Accumulated Amortization Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Metsera [Member] Metsera [Member] Metsera Current portion of long-term debt Long-Term Debt, Current Maturities Productivity and Operational Efficiencies [Member] Exit Costs [Member] Other Restructuring [Member] License Agreements and Other [Member] Licensing Agreements And Other [Member] Licensing Agreements And Other [Member] Indefinite-lived intangible assets, period decrease Intangible Asset, Indefinite-Lived, Period Increase (Decrease) Amount of Gains/(Losses) Reclassified from OCI into OID and COS Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax ModernaTX U.S. Patent Infringement Case [Member] ModernaTX U.S. Patent Infringement Case [Member] ModernaTX U.S. Patent Infringement Case Litigation Case [Axis] Litigation Case [Axis] Unrealized holding gains/(losses) on derivative financial instruments, net Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax Noncontrolling Interests [Member] Noncontrolling Interest [Member] Domestic Plan [Member] Domestic Plan [Member] Tukysa [Member] Tukysa [Member] Tukysa Unsecured Debt [Member] Unsecured Debt [Member] Other comprehensive income/(loss), before tax Other Comprehensive Income (Loss), before Tax Long-term debt Long-Term Debt Asset Impairment Charges [Member] Asset Impairments [Member] Asset impairments [Member] Vyndaqel Litigation Case [Member] Vyndaqel Litigation Case [Member] Vyndaqel Litigation Case Net cash provided by/(used in) investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Costs and expenses: Costs and Expenses [Abstract] Security Exchange Name Security Exchange Name Total Payments to Former Metsera Shareholders [Member] Total Payments to Former Metsera Shareholders [Member] Total Payments to Former Metsera Shareholders Biopharma [Member] Biopharma Segment [Member] Biopharma Segment [Member] Purchases of long-term investments Payments to Acquire Marketable Securities Total liabilities Liabilities, Fair Value Disclosure Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Name Outstanding Recovery, Individual Name Reclassification adjustments for (gains)/losses included in net income/(loss) Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Milestone Payments [Axis] Milestone Payments [Axis] Milestone Payments FSME-IMMUN/TicoVac [Member] FSME/IMMUN-TicoVac [Member] FSME/IMMUN-TicoVac Geographical [Domain] Geographical [Domain] Long-term equity securities held in trust Equity Securities, FV-NI, Restricted, Noncurrent Equity Securities, FV-NI, Restricted, Noncurrent Indefinite-lived intangible assets Intangible Asset, Excluding Goodwill, Indefinite-Lived Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Certain legal matters, net Gain (Loss) from Litigation Settlement Reclassification, Type [Axis] Reclassification, Type [Axis] Held-to-maturity securities, debt maturities, within 1 year, fair value Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Non-cash expenditures, percentage of expected cost Restructuring and Related Cost, Non-Cash Expenditures, Percentage of Expected Cost Restructuring and Related Cost, Non-Cash Expenditures, Percentage of Expected Cost Manufacturing Optimization Program [Member] Manufacturing Optimization Program [Member] Manufacturing Optimization Program Long-term investments Total Long-term investments Other Long-Term Investments Zavicefta (Outside the U.S. and Canada) [Member] Zavicefta [Member] Zavicefta Total long-term debt, principal amount Long-Term Debt, Gross Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Weighted-average shares--diluted (in shares) Weighted-average number of common shares outstanding––Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Entity Emerging Growth Company Entity Emerging Growth Company Pension and postretirement benefit obligations Liability, Defined Benefit Plan, Noncurrent Underlying Security Market Price Change Underlying Security Market Price Change, Percent Zithromax [Member] Zithromax Zmax [Member] Zithromax / Zmax [Member] Held-to-maturity securities, gross unrealized losses Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss Contributions by employer Defined Benefit Plan, Plan Assets, Contributions by Employer Payment period (in years) Research And Development Arrangement, Contingent Payments, Payment Period Research And Development Arrangement, Contingent Payments, Payment Period All other Primary Care [Member] Other Primary Care Products [Member] Other Primary Care Products Treasury Stock [Member] Treasury Stock, Common [Member] Intangible Asset, Goodwill and Other [Abstract] Intangible Asset, Goodwill and Other [Abstract] Total accrued rebates and other sales-related accruals Rebates And Other Sales-Related Accruals Certain accrued rebates and accrued sales returns Employee terminations Severance Costs Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS, excluded from effectiveness testing Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax Debt securities, fair value Debt Securities, Available-for-Sale and Held-to-Maturity, after Allowance for Credit Loss Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Indefinite-lived Intangible Assets, Major Class Name [Domain] Intangible Asset, Indefinite-Lived, Class [Domain] Litigation Status [Domain] Litigation Status [Domain] All Executive Categories All Executive Categories [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Schedule of Net Periodic Benefit Costs Schedule of Net Benefit Costs [Table Text Block] Contingent value right, fair value Business Combination, Consideration Transferred, Contingent Value Right Business Combination, Consideration Transferred, Contingent Value Right Schedule of Basic and Diluted Earnings (Loss) Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Segment, Geographic and Other Revenue Information Segment Reporting [Text Block] Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income Statement Location [Axis] Location, Statement of Income, Balance [Axis] Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Income /loss) from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Gain Contingencies [Table] Gain Contingencies [Table] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Business Combination [Line Items] Business Combination [Line Items] Net periodic benefit costs/(credits) recorded in Other (income)/deductions––net Net periodic benefit cost/(credit) reported in income Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Sulperazon (Outside the U.S. and Canada) [Member] Sulperazon [Member] Sulperazon [Member] Other accruals Other Accruals Other Accruals Primary Care [Member] Primary Care [Member] Primary Care Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Loss contingency, patents ruled invalid Loss Contingency, Patents Ruled Invalid Loss Contingency, Patents Ruled Invalid Bayer Cropscience LLC, Monsanto Company and Monsanto Technology, LLC US Patent Infringement Case Bayer Cropscience LLC, Monsanto Company and Monsanto Technology, LLC US Patent Infringement Case [Member] Bayer Cropscience LLC, Monsanto Company and Monsanto Technology, LLC US Patent Infringement Case Exercise Price Award Exercise Price Schedule of Restructuring and Related Costs [Table] Restructuring Cost [Table] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Segment Reporting [Line Items] Segment Reporting [Line Items] Hospital and Biosimilars [Member] Hospital and Biosimilars [Member] Hospital and Biosimilars Document Quarterly Report Document Quarterly Report Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Debt securities maturities, over 5 years, fair value Debt Securities Maturities, After Year Five, Fair Value Debt Securities Maturities, After Year Five, Fair Value Debt securities, gross unrealized losses Debt Securities, Accumulated Gross Unrealized Loss Debt Securities, Accumulated Gross Unrealized Loss Inflectra [Member] Inflectra [Member] Inflectra [Member] Curtailments Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment Payments on long-term debt Repayments of Long-Term Debt Investments by Classification Type Marketable Securities [Table Text Block] Net unamortized discounts, premiums and debt issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Equity-method investments Equity Method Investments Balance, beginning Balance, ending Restructuring Reserve Equity Component [Domain] Equity Component [Domain] Foreign exchange contracts [Member] Foreign Exchange Contract [Member] Adoption Date Trading Arrangement Adoption Date Schedule of Other (Income)/Deductions - Net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Counterparty Name [Domain] Counterparty Name [Domain] Short-term investments Short-Term Investments [Abstract] Restructuring Type [Axis] Restructuring Type [Axis] Equity securities with readily determinable fair values Equity Securities, FV-NI, Current Notes Due 2032, 3.250% [Member] Notes Due 2032, 3.250% [Member] Notes Due 2032, 3.250% Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Finite-lived intangible assets, period increase Intangible Asset, Finite-Lived, Period Increase (Decrease) Held-to-maturity securities, fair value Debt Securities, Held-to-Maturity, Fair Value Other financing activities, net Proceeds from (Payment for) Other Financing Activity Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Selling, informational and administrative expenses Selling, General and Administrative Expense Type of Restructuring [Domain] Type of Restructuring [Domain] Business Combination [Domain] Business Combination [Domain] Contingencies and Certain Commitments Commitments and Contingencies Disclosure [Text Block] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] All Adjustments to Compensation All Adjustments to Compensation [Member] Other Business Activities [Member] Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] Business Combination [Axis] Business Combination [Axis] Acquisition, In-Licensing Arrangement, Sale of Investment and Research and Development Arrangement Research, Development, and Computer Software Disclosure [Text Block] Net cash provided by/(used in) operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Collateral received Securities Received as Collateral Income Statement [Abstract] Income Statement [Abstract] Document Transition Report Document Transition Report Restructuring Plan [Domain] Restructuring Plan [Domain] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Intangible Asset, Finite-Lived Intangible Asset, Finite-Lived [Table Text Block] City Area Code City Area Code Prior Service (Costs)/Credits and Other [Member] Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member] Name Forgone Recovery, Individual Name Research and Development [Abstract] Reclassification Other [Member] Reclassification, Other [Member] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Notes Due 2045, 4.250% [Member] Notes Due 2045, 4.250% [Member] Notes Due 2045, 4.250% Lorbrena [Member] Lorbrena [Member] Lorbrena Amortization of prior service cost/(credit) Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Research and Development, Contract to Perform for Others [Table] Research and Development, Contract to Perform for Others [Table] Micro Labs, Changzhou and Biocon Patent Infringement Case [Member] Micro Labs, Changzhou and Biocon Patent Infringement Case [Member] Micro Labs, Changzhou and Biocon Patent Infringement Case Asset impairments Restructuring, Asset Impairment Charges Restructuring, Asset Impairment Charges Cumulative impairment losses and downward price adjustments on equity securities Equity Securities Without Readily Determinable Fair Value, Impairment Loss And Downward Price Adjustment, Cumulative Amount Equity Securities Without Readily Determinable Fair Value, Impairment Loss And Downward Price Adjustment, Cumulative Amount Measurement Basis [Axis] Measurement Basis [Axis] Reporting Unit [Axis] Reporting Unit [Axis] Unrealized holding gains/(losses) on available-for-sale securities, net OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax Deferred revenue recognized Contract with Customer, Liability, Revenue Recognized Available-for-sale securities, debt maturities, within 1 year, fair value Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Subsequent Event Type [Domain] Subsequent Event Type [Domain] Income taxes payable Taxes Payable, Current Available-For-Sale Securities [Member] AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Entity Current Reporting Status Entity Current Reporting Status Net cash provided by/(used in) financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Restructuring charges/(credits): Restructuring Charges [Abstract] Total Shareholder Return Amount Total Shareholder Return Amount Other changes in assets and liabilities, net of acquisitions and divestitures Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital Discontinued operations––net of tax (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Derivatives qualifying as hedges, tax, total Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax Cash Flow Hedging [Member] Cash Flow Hedging [Member] Number of milestone payments Number of Milestone Payments Number of Milestone Payments Indefinite-lived Indefinite-Lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure Adcetris [Member] Adcetris [Member] Adcetris Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less Proceeds from (Repayments of) Short-Term Debt, Maturing in Three Months or Less Loss contingency, patents ruled invalid and subsequently revoked Loss Contingency, Patents Ruled Invalid And Subsequently Revoked, Number Loss Contingency, Patents Ruled Invalid And Subsequently Revoked, Number Adjustments to reconcile net income from continuing operations before allocation to noncontrolling interests to net cash provided by/(used in) operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Pre-tax loss expected to be reclassified within the next 12 months Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Financing Activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Property, plant and equipment, net of accumulated depreciation: 2026—$18,104; 2025—$17,386 Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Interest cost Defined Benefit Plan, Interest Cost Financial Instruments [Domain] Financial Instruments [Domain] Asset Derivative Asset Padcev [Member] Padcev [Member] Padcev Schedule of Tax Provision/(Benefit) on Other Comprehensive Income (Loss) Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block] Intangible Asset, Finite-Lived, Class [Axis] Intangible Asset, Finite-Lived, Class [Axis] Identifiable Intangible Assets, Net and Goodwill Intangible Asset and Goodwill [Text Block] Underlying Securities Award Underlying Securities Amount Less: Comprehensive income/(loss) attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Estimated Fair Value [Member] Estimate of Fair Value Measurement [Member] Oncology [Member] Oncology [Member] Oncology [Member] Financial Instruments Financial Instruments Disclosure [Text Block] Subsegments [Axis] Subsegments [Axis] Other investing activities, net Payment for (Proceeds from) Other Investing Activity Total other noncurrent liabilities Liabilities, Noncurrent, Fair Value Disclosure Liabilities, Noncurrent, Fair Value Disclosure Paxlovid and Comirnaty [Member] Paxlovid and Comirnaty [Member] Paxlovid and Comirnaty Segment Reporting [Table] Segment Reporting [Table] Other comprehensive income (loss), available-for-sale securities, before tax, total OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax International Emerging Markets [Member] International Emerging Markets [Member] International Emerging Markets [Member] Contingent consideration liabilities Business Combination, Contingent Consideration, Liability, Current Schedule of Available-for-sale Securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Other current assets Other Assets, Current Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Fair value, beginning Fair value, ending Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Reclassification adjustments for (gains)/losses included in net income/(loss) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax Current Fiscal Year End Date Current Fiscal Year End Date Held-to-maturity securities, amortized cost Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Derivative [Line Items] Derivative [Line Items] Expected restructuring cost Restructuring and Related Cost, Expected Cost Repatriation tax liability US Public Law 115-97, Transition Tax for Accumulated Foreign Earnings, Liability Total Intangible Assets, Fair Value Disclosure Intangible Assets, Fair Value Disclosure Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Cash dividends declared per share (in dollars per share) Common Stock, Dividends, Per Share, Declared Entity File Number Entity File Number Contractual Maturities of Available-for-sale and Held-to-maturity Debt Securities Investments Classified by Contractual Maturity Date [Table Text Block] Reclassification adjustments for (gains)/losses included in net income/(loss) Derivative, Amount of Gains/(Losses) Reclassified from OCI into OID and COS (Loss) gain reclassified from OCI into COS Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Measure: Measure [Axis] Pension and other postretirement benefit plans, net prior service cost (credit), tax Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Tax Special termination benefits Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits Beginning balance (in shares) Ending balance (in shares) Treasury Stock, Common, Shares Equity Components [Axis] Equity Components [Axis] Income taxes Income Tax Paid, after Refund Received Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service costs and other, before tax Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax Entity Interactive Data Current Entity Interactive Data Current Less: Net income attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Entity Small Business Entity Small Business Comprehensive income/(loss) attributable to Pfizer Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Settlements and other Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Held-to-maturity debt securities Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Noncurrent MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Other taxes payable Liability for Uncertainty in Income Taxes, Noncurrent Other noncurrent assets Other Assets, Noncurrent Document Type Document Type Acquisitions of businesses, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Schedule of Indefinite Lived Intangible Assets Intangible Asset, Indefinite-Lived [Table Text Block] Acquired in-process research and development expenses Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff Total long-term investments Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments Intangible asset impairment charge Impairment Intangible Asset, Excluding Goodwill, Impairment Loss Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Proceeds from issuance of long-term debt Proceeds from Issuance of Long-Term Debt Local Phone Number Local Phone Number Deferred revenues, noncurrent Contract with Customer, Liability, Noncurrent Postretirement Plans [Member] Other Postretirement Benefits Plan [Member] Other Financial Information Additional Financial Information Disclosure [Text Block] Short-term investments Total Short-term investments Other Short-Term Investments Net Investment Hedging [Member] Net Investment Hedging [Member] Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss) Earnings Income from continuing operations before provision/(benefit) for taxes on income Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Debt securities, gross unrealized gains Debt Securities, Accumulated Gross Unrealized Gain Debt Securities, Accumulated Gross Unrealized Gain Commitments and Contingencies Commitments and Contingencies Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted Executive Category: Executive Category [Axis] Corporate, Time Deposits and Other [Member] Corporate, Time Deposits and Other [Member] Corporate, Time Deposits and Other Tax provision/(benefit) on other comprehensive income/(loss) Tax provision/(benefit) on other comprehensive income/(loss) Other Comprehensive Income (Loss), Tax Counterparty Name [Axis] Counterparty Name [Axis] Liabilities and Equity Liabilities and Equity [Abstract] Inventories Inventories Inventory, Net Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Cash paid during the period for: Supplemental Cash Flow Information [Abstract] Intercompany inventory sales [Member] Foreign Exchange Future [Member] PEO Name PEO Name Other short-term borrowings, principal amount Other Short-Term Borrowings Derivative Financial Instruments [Member] Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Entity Tax Identification Number Entity Tax Identification Number Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instruments and Hedging Activities Disclosures [Table] Xtandi [Member] Xtandi [Member] Xtandi Inlyta [Member] Inlyta [Member] Inlyta [Member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Additions Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Discontinued operations––net of tax (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Comprehensive income/(loss) before allocation to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Prevnar Family [Member] Prevnar Prevenar Family [Member] Prevnar/Prevenar Family 13 [Member] Elrexfio [Member] Elrexfio [Member] Elrexfio Subsegments Consolidation Items [Domain] Subsegments Consolidation Items [Domain] Weighted-average common-share equivalents excluded from computation of diluted LPS (in shares) Weighted-Average Shares Excluded from Computation of Earnings Per Share, Amount Weighted-Average Shares Excluded from Computation of Earnings Per Share, Amount Net income/(loss) attributable to Pfizer Inc. common shareholders (in dollars per share) Earnings Per Share, Basic Total current assets Assets, Current Insider Trading Arrangements [Line Items] Long-term debt Total long-term debt, carried at historical proceeds, as adjusted Long-Term Debt, Excluding Current Maturities Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Liability Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) Trade accounts receivable, net of allowance for doubtful accounts: 2026—$423; 2025—$427 Accounts Receivable, after Allowance for Credit Loss, Current Schedule of Short-term Borrowings Schedule of Short-Term Debt [Table Text Block] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Schedule Of Available For Sale Securities And Held To Maturity Securities [Table] Schedule Of Available For Sale Securities And Held To Maturity Securities [Table] Schedule of Available for sale Securities and Held to maturity Securities [Table] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Contingent value right Business Combination, Contingent Consideration, Liability Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Cover [Abstract] Cover [Abstract] Equity Awards Adjustments Equity Awards Adjustments [Member] Hedging Relationship [Domain] Hedging Relationship [Domain] Noncurrent derivative liabilities Derivative Liability, Noncurrent Short-term borrowings, including current portion of long-term debt: 2026—$2,605; 2025—$2,997 Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted Debt, Current Equity securities with readily determinable fair values Equity Securities, FV-NI, Noncurrent Other (income)/deductions––net Other (income)/deductions––net Other Nonoperating Income (Expense) Shareholders' Equity [Member] Parent [Member] Hedging Designation [Domain] Hedging Designation [Domain] Class of Stock [Domain] Class of Stock [Domain] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] IPR&D [Member] In Process Research and Development [Member] Eliquis [Member] Eliquis [Member] Eliquis [Member] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Realigning Our Cost Base Program - Research and Development [Member] Realigning Our Cost Base Program - Research and Development [Member] Realigning Our Cost Base Program - Research and Development Tax Matters Income Tax Disclosure [Text Block] Trade accounts payable Accounts Payable, Current Other adjustments, net Other Noncash Income (Expense) Schedule of Balance Sheet Classification of Accruals Schedule Of Medicare Rebates, Medicaid And Related State Program Rebates, Performance-Based Contract Rebates, Chargebacks, Sales Allowances And Sales Returns And Cash Discounts [Table Text Block] Schedule Of Medicare Rebates, Medicaid And Related State Program Rebates, Performance-Based Contract Rebates, Chargebacks, Sales Allowances And Sales Returns And Cash Discounts [Table Text Block] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Other comprehensive income, cash flow hedge, gain (loss), before tax, total Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax Retirement Plan Type [Domain] Retirement Plan Type [Domain] Insurance contracts Life Settlement Contracts, Fair Value Entity Filer Category Entity Filer Category Contingent consideration liabilities Business Combination, Recognized Liability Assumed, Contingent Liability Nurtec ODT/Vydura [Member] Nurtec ODT/Vydura [Member] Nurtec ODT/Vydura Paxlovid [Member] Paxlovid, EUA-Labeled [Member] Paxlovid, EUA-Labeled Derivatives not designated as hedging instruments [Member] Derivative Financial Instruments Not Designated as Hedges [Member] Not Designated as Hedging Instrument [Member] Restructuring charges and certain acquisition-related costs Restructuring charges and certain acquisition-related costs Restructuring Charges And Acquisition Related Costs This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities. Net income/(loss) before allocation to noncontrolling interests Net income/(loss) before allocation to noncontrolling interests Net income/(loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Business acquisition, per share in cash (in dollars per share) Business Combination, Price Per Share ViiV [Member] ViiV Healthcare Limited [Member] ViiV Healthcare Limited [Member] Noncurrent deferred tax assets and other noncurrent tax assets Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent Liability Derivative Liability Entity Address, Address Line One Entity Address, Address Line One Proceeds from redemptions/sales of short-term investments Proceeds from Sale, Maturity and Collection of Short-Term Investments Provision/(benefit) for taxes on income/(loss) Income Tax Expense (Benefit) Fair Value Hedging [Member] Fair Value Hedging [Member] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and development expenses Research and development expenses Research and Development Expense (Excluding Acquired in Process Cost) Net deferred tax liabilities Business Combination, Recognized Liability Assumed, Deferred Tax Liability AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Abrysvo [Member] Abrysvo [Member] Abrysvo Statement [Table] Statement [Table] Reconciling Items [Member] Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member] Derivative term of contract Derivative, Contract Term Interest income Investment Income, Interest Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Talzenna [Member] Talzenna [Member] Talzenna Basis of Presentation and Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Interest rate hedges Interest Paid (Received), Interest Rate Hedges Interest Paid (Received), Interest Rate Hedges